Nothing Special   »   [go: up one dir, main page]

EP4168452A4 - Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof - Google Patents

Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof

Info

Publication number
EP4168452A4
EP4168452A4 EP21824799.7A EP21824799A EP4168452A4 EP 4168452 A4 EP4168452 A4 EP 4168452A4 EP 21824799 A EP21824799 A EP 21824799A EP 4168452 A4 EP4168452 A4 EP 4168452A4
Authority
EP
European Patent Office
Prior art keywords
immunoconjugates
antibodies
antibody fragments
active anti
conditionally active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21824799.7A
Other languages
German (de)
French (fr)
Other versions
EP4168452A1 (en
Inventor
Jay M Short
Gerhard Frey
Hwai Wen Chang
Jing Wang
Chao Xing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioatla Inc
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of EP4168452A1 publication Critical patent/EP4168452A1/en
Publication of EP4168452A4 publication Critical patent/EP4168452A4/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21824799.7A 2020-06-18 2021-06-15 Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof Pending EP4168452A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040913P 2020-06-18 2020-06-18
PCT/US2021/037400 WO2021257542A1 (en) 2020-06-18 2021-06-15 Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof

Publications (2)

Publication Number Publication Date
EP4168452A1 EP4168452A1 (en) 2023-04-26
EP4168452A4 true EP4168452A4 (en) 2024-07-10

Family

ID=79268294

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21824799.7A Pending EP4168452A4 (en) 2020-06-18 2021-06-15 Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof

Country Status (11)

Country Link
US (1) US20230242662A1 (en)
EP (1) EP4168452A4 (en)
JP (1) JP2023531189A (en)
KR (1) KR20230023800A (en)
CN (1) CN115702167A (en)
AU (1) AU2021292486A1 (en)
CA (1) CA3182384A1 (en)
IL (1) IL298902A (en)
MX (1) MX2022016197A (en)
TW (1) TW202214696A (en)
WO (1) WO2021257542A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040683A1 (en) * 2014-09-12 2016-03-17 The Regents Of The University Of California Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2810016A1 (en) * 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
WO2018089807A2 (en) * 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
CN109535260B (en) * 2018-11-22 2021-08-10 东南大学 Human chimeric antigen receptor targeting CD46 and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040683A1 (en) * 2014-09-12 2016-03-17 The Regents Of The University Of California Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics

Also Published As

Publication number Publication date
CN115702167A (en) 2023-02-14
KR20230023800A (en) 2023-02-17
AU2021292486A1 (en) 2023-02-09
MX2022016197A (en) 2023-04-05
US20230242662A1 (en) 2023-08-03
CA3182384A1 (en) 2021-12-23
JP2023531189A (en) 2023-07-21
WO2021257542A1 (en) 2021-12-23
TW202214696A (en) 2022-04-16
EP4168452A1 (en) 2023-04-26
IL298902A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
IL282060A (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
EP3753951A4 (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
IL291299A (en) Anti-tnfr2 antibodies, composotions comprising same and uses thereof
ZA202206885B (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3455261A4 (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
ZA202004907B (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
GB202017058D0 (en) Antibodies and uses thereof
EP4253414A4 (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
EP4081548A4 (en) Anti-sirp? monoclonal antibodies and uses thereof
EP4146272A4 (en) Covid-19 antibodies and uses thereof
IL288753A (en) Conditionally active anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereof
EP4190819A4 (en) Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
EP4247419A4 (en) Anti-marco antibodies and uses thereof
IL285953A (en) Antibody-drug conjugates including antibody against human dlk1, and use thereof
EP4132569A4 (en) Anti-phf-tau antibodies and uses thereof
EP3919516A4 (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
IL310535A (en) Anti-gdf15 antibodies, compositions and uses thereof
IL310012A (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
EP4168452A4 (en) Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof
IL316008A (en) Anti-tigit-anti-pvrig bispecific antibody, pharmaceutical composition thereof and use thereof
IL279086A (en) Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP4093774A4 (en) Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof
EP4347646A4 (en) Anti-cd98 antibodies and uses thereof
EP4132952A4 (en) Monoclonal antibodies and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240607

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20240604BHEP

Ipc: A61P 35/00 20060101ALI20240604BHEP

Ipc: A61K 51/10 20060101ALI20240604BHEP

Ipc: A61K 47/68 20170101ALI20240604BHEP

Ipc: C07K 16/28 20060101AFI20240604BHEP